Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: A multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial
Uwe Platzbecker, Raymond S.M. Wong, Amit Verma, Camille Abboud, Sergio Araujo, Tzeon Jye Chiou, John Feigert, Su Peng Yeh, Katharina Götze, Norbert Claude Gorin, Peter Greenberg, Suman Kambhampati, Yoo Jin Kim, Je Hwan Lee, Roger Lyons, Marco Ruggeri, Valeria Santini, Gregory Cheng, Jun Ho Jang, Chien Yuan ChenBrendan Johnson, John Bennett, Frank Mannino, Yasser Mostafa Kamel, Nicole Stone, Souria Dougherty, Geoffrey Chan, Aristoteles Giagounidis
Dive into the research topics of 'Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: A multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial'. Together they form a unique fingerprint.